-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 24, according to the official website of CDE, Sansheng Guojian PD-1/HER2 double antibody SSGJ-705 for injection was applied for clinical application (acceptance number: CXSL2101211)
.
This is the second PD-1/HER2 dual antibody declared after Cinda Biologics IBI315
Currently, immune checkpoint blocking therapies, including anti-PD-1/PD-L1 antibodies, have shown significant clinical benefits in a variety of cancers, but their effectiveness is usually limited to 20%-30% of patients , And most patients develop resistance to treatment over time
.
In invasive breast cancer, about 20%-25% of cases are HER2 positive, which is characterized by high invasiveness and poor patient prognosis.
Most patients will still have recurrence or resistance after receiving existing anti-HER2 therapies.
Medicine
SSGJ-705 is a recombinant anti-HER2 x anti-PD-1 bispecific antibody injection independently developed by Sansheng Guojian using its own bispecific antibody platform
.
The drug targets both HER2 and PD-1 targets at the same time, combining HER2 targeted therapy with immune checkpoint blocking therapy to more effectively treat HER2-positive solid tumors
On June 18, Sansheng Guojian announced a phase I evaluation of the safety, tolerability, pharmacokinetics and potential anti-tumor effects of SSGJ-705 in patients with advanced or metastatic HER2-positive solid tumors , Multi-center, open-label, first human clinical trial has been approved by the U.
